Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

Download full press releaseEN
Download volledig persberichtNL

With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world.

- Anurag Relan - Chief Medical Officer

Attachments

  • Original document
  • Permalink

Disclaimer

Pharming Group NV published this content on 23 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2021 07:32:05 UTC.